Monosodium Luminol for Improving Brain Function in Gulf War Illness
Technical Report,30 Sep 2014,29 Sep 2015
Texas A and M University System College Station United States
Pagination or Media Count:
The goal of this project is to ascertain whether administration of monosodium luminol-GVT MSL-GVT, an antioxidant drug from Bach Pharma in a rat model of Gulf war illness GWI would alleviate mood and memory dysfunction and anxiety associated with Gulf war illness GWI. Specific Aim 1 studies are focused on quantifying the efficacy of different doses of MSL-GVT for suppressing oxidative stress and inflammation and improving neurogenesis in the hippocampus of rats exposed to GWI-related GWIR chemicals and stress GWI-rats. Specific Aim 2 studies are focused on examining whether long-term administration of an apt dose of MSL-GVT would alleviate mood and memory dysfunction and anxiety in GWI-rats, using a battery of behavioral tests. During the past year, a portion of experiments for Specific Aim 1 was performed 1 Exposure of rats to GWIR-chemicals and moderate stress. 2 Oral administration of different doses of MSL-GVT, 4-months after the exposure. 3 Mood and memory function analyses using a few behavioral tests. 4 Analyses of oxidative stress using biochemical and molecular biological assays. The data collected so far suggest that administration of higher doses of MSLGVT to GWI-rats improves mood and memory function with decreased concentration of malondialdehyde a by product of oxidative stress and normalized expression of oxidative stress responsive genes.